$10 to $15 is fair value. ACOR depends on one drug and that one drug is in trouble now.
LOL... The VRX statement was perhaps a bad joke. I'm surprised anyone does business with them.
Calling ACOR a 1 trick pony is misleading. They actually have several drugs approved and selling on the market, but the lions share of the revenue does come from one drug. That drug could become a blockbuster as it's being tested for uses with other conditions. ACOR has a robust pipeline - with several drugs showing potential for approval.
All that aside.... That one drug - makes ACOR profitable! Unlike many other pharma's, this one drug can support the company while we wait to see if others get approved.
First, VRX is almost in BK because of its huge debt.
Second, ACOR is struggling to get some income and it has to do some cutting in every area including development.
Third, ACOR has been one trick pony and that pony is getting sick and becomes weak.
ACOR has to drop more to be attractive. Prices between $15 to $20 should be interesting.
It's hard to find another bio tech this attractively priced with sustainable revenues and a promising pipeline - trading at such a low p/e.
Maybe valeant will scoop this up... probably not.
04/29/2016 Buy 1,000 Shares of ACOR Limit at $25.50 (Day) Filled at $25.50
Was going to buy into this last year and glad I held out for this price. I was all about it at 41$ considering all they do... NOW, BB up their holdings 226% and in for a cool 150M... Got to be some major movement on this with time. @ 28 and no doubt you will get 40$ within a year...
SNSS too... just need research on it. ACOR is solid play for a 25% increase...
Develops and commercializes novel pain management therapies
NeurogesX, Inc. is a biopharmaceutical company, which is focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs.
Its product Qutenza, a synthetic capsaicin-based dermal patch designed to manage pain associated with peripheral neuropathic pain conditions.
NeurogesX was founded by Wendye R. Robbins on May 28, 1998 and is headquartered in San Mateo, CA.
Name Age Since Title
Linda L. Schock - 2009 Director-Commercial Operations
Vote Quantity Float Company-owned shares Total Float
Share A 1 33,329,119 29,228,798 87.7% 0 0.0% 87.7%
Name Equities %
Charles A Henriques 4,966,649 14.9%
KCG Americas LLC 1,986,078 5.96%
Harel-Pia Mutual Funds Ltd. 101,107 0.30%
Meitav Ds Mutual Funds Ltd. 7,014 0.021%
Fidelity Management & Research Co.
In past 3 years, ACOR has put $277m or $6.4 per share in its R&D. It has 3 products in phase III. These are investments that are not visible to many.
After all, ACOR has very small market cap compare to many in the sector. Its cash flow is high enough to provide money for its R&D.
New acquisition will add an approved money making product (double digit loyalty) plus another product in phase III with a high potential.
It is cash flow positive, more cash than debt. Right combination for acquisition or growth to be a mid cap.
Sentiment: Strong Buy
Revenue is growing. Income is positive and large enough to provide money for its huge R&D.
It is cash positive without any debt with very low shares outstanding and low market cap.
It has 3 drugs in phase 3 and results will be known by end of this year.
It is one of the best I ever seen in the sector. It will be target of acquisition one way or another.
Why are you wasting your time here.
That 14.9% is less than 2k of ACOR.
NeurogesX is one single penny per share and soon becomes zero per share.
1- ACOR patent challenges is going well for ACOR and the hedge fund just wants to mud the waters and so it can fish.
2- Ampyra has orphan drug designation and it is untouchable until mid 2017. Only one patent is challenges and ACOR will win it or settle it as it did with other companies.
3- ACOR revenue and income are rising and cash flow is more than enough to fund its development.
4- ACOR has 3 drugs in phase III and it has spent a lot of money, about 40% of its revenue for drug development.
5- ACOR has a clean balance sheet and its cash exceeds its debt currently.
6- ACOR is acquiring Biotie which adds am approved drug and one promising drug in phase III.
7- ACOR share outstanding is very low which leads to low market cap. It should trade much higher than current prices to be comparable to other small caps even after recent discount for most biotechs.
Sentiment: Strong Buy
I cannot believe that ACOR is trading at current prices.
34% of revenue goes to R&D and that is a huge investment that will reward the company in near and far future.